Doses that induced anti-tumor activity elevated both PLK4 and p21 protein levels in a dose- and time-dependent manner, confirming target modulation by RP-1664 at biologically active exposures (Figure 6C and Extended Data Figure 6C-E). The gene discussed is CDKN1A; the disease is neoplasm.